Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in patients with severe obesity and type-2 diabetes (T2D). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.